Ting Zhou

Corporate Expansion – Greenfield and Brownfield Investments, M&As, Startup Financings, JVs, and Other Investments

• Represented LANXESS in the sale of its Urethane Systems business in the U.S. (as part of its global sale of such business) to Japanese UBE Corporation.
• Represented one of the world’s largest solar panel companies in its $200 million+ investment to establish a new solar panel assembly facility in the U.S. in 2023.
• Represented one of the world’s largest EV battery components companies in its $1 billion investment to establish a new EV battery component manufacturing facility in the U.S. in 2022.
• Represented multiple pharmaceutical and biotech companies in securing debt and equity financings, encompassing a range of instruments such as SAFE agreements, Series Seed, convertible notes, and Series A, B, and C rounds of financing.
• Advised The Coca-Cola Company in its complex reorganization of its bottling business in China.
• Advised Guangzhou R&F Properties Co., Ltd. in the disposal of its equity interest in Guangzhou International Airport R&F Integrated Logistics Park with the property value at approximately RMB 7.3 billion (US$1.14 billion) to The Blackstone Group Inc.
• Represented WinIt America in its investments in, and establishment of, multiple warehouse and logistics facilities in New Jersey, Kentucky, Texas, Arizona and Atlanta since 2019.
• Represented H. J. Baker Sulphur Holdings, LLC in its acquisition and financing of Oxbow Sulphur Inc. and its worldwide sulphur business affiliates.
• Represented Eddingpharm Group, a leading pharmaceutical contract sales company in China, in connection with its acquisition of certain pharmaceutical product rights in China from Eli Lilly.
• Represented a leading non-profit biomedical research organization in the United States in connection with its proposed joint venture and collaborative research initiatives with business partners and universities in China.
• Represented a restaurant chain company in its group reorganization, business expansion, franchise, and other various corporate matters.
• Represented Yili Group, the largest dairy products company in Asia, in its bidding for Stonyfield, the No. 1 organic yogurt maker in the United States, a subsidiary of Danone.
• Represented CDH Investments, a top Chinese PE firm, in connection with multiple acquisitions and investments.
• Represented a New York based IVF clinic center in its separation of non-clinical assets and receiving investments from international investors.
• Represented a Hong Kong Stock Exchange listed real estate conglomerate in connection with its acquisitions of multiple real estate portfolios in the United States, including retirement living facilities, student housing projects and other commercial and mixed use properties.
• Represented certain shareholders of a Minnesota-based private marketing and sales company in the proposed sale of their controlling interests in the company to a Chinese public company.
• Represented a U.S. maritime technology company in its sale to a Beijing-based Chinese public company.
• Represented Johnson Controls in selling its China related automotive electronics business (a part of its global sales of automotive electronics business) to Visteon.
• Represented a US leading auto components manufacturer, in selling part of its equity interest in a joint venture to its Chinese partner.
• Represented a major multinational medical device manufacturer in the acquisition of its distributor.
• Represented a leading Chinese ore processing company in its joint venture with a major Dutch company and a major US company.

Commercial Contracts (with a focus on worldwide and U.S.-China life sciences licensing and collaboration transactions)

• Represented a leading global biopharmaceutical company in negotiating a mutual licensing agreement with a leading U.S. biotechnology company for two bifunctional sialidase programs.
• Represented multiple U.S. biotech companies in negotiating out-licensing agreements with Asian licensees for vaccine technologies and products.
• Represented a leading Chinese pharmaceutical company in negotiating an in-licensing agreement with a U.S. company for technologies and products to treat breast cancer.
• Represented a leading Chinese pharmaceutical company in negotiating an in-licensing agreement with a Belgian company for technologies and products to treat diabetic macular edema.
• Represented a leading Chinese specialty pharmaceutical company in negotiating an in-licensing agreement with a diversified biopharmaceutical company for technologies and products to treat chronic obstructive pulmonary disease.
• Represented a leading Chinese pharmaceutical company in negotiating an in-licensing agreement and a supply agreement with a leading biopharmaceutical company for technologies and products to treat neonatal respiratory disease.
• Represented a U.S. startup in negotiating an in-licensing agreement with a Japanese biopharmaceutical company for technologies and products to treat certain cancers.
• Represented a Chinese dental startup in negotiating an in-licensing agreement for invisible aligner with a U.S. company.
• Representing multiple biotech companies and pharmaceutical companies in negotiating supply agreements and distribution agreements.
• Represented a Chinese consumer product manufacturer and its U.S. subsidiary in the negotiation of multiple supply agreements with U.S. customers.

General Corporate – Structuring, Corporate Formation, Governance

• Representing multiple biotech companies based in California, Massachusetts, and New Jersey in various matters relating to their operations in the U.S. and cross-border commercial contracts with third parties outside of the U.S.
• Representing a leading baby product company in its various matters relating to corporate structuring, governance, employment, IP, compliance and legal risk management.
• Counseled Ninebot Limited, a portfolio company of Xiaomi Technologies and Sequoia Capital, in its general corporate, employment, IP and other matters.
• Represented Fantasia Group, China’s largest property management conglomerate, in its expansion and operations in the U.S.
• Represented one of the largest dairy products companies in China in its expansion in the U.S.
• Represented a leading infrastructure construction company in China in its expansion in the U.S.

Private Equity Fund – Formation and Investments

• Represented a sponsor group in the organization of a $150 million private equity fund.
• Represented an investment fund in its secondary transactions acquiring over $500 million of limited partner commitments.
• Represented a family office in its investments in multiple single-investment SPV funds organized to invest in China based pre-IPO, growth-stage companies.
• Represented a Chinese state-owned asset management company (with AUM of over RMB one trillion yuan) in its investment in a $650 million private debt fund.
• Represented a private equity fund (with AUM of $250 million) in its reorganization.

U.S.-China Regulatory Compliance: National Security, Export Control, and U.S. Sanctions

• Represented a leading power transmission product company in CFIUS analysis related to its business expansion in the U.S.
• Represented one of the world’s largest solar panel companies in CFIUS analysis related to its business expansion in the U.S.
• Represented a leading cleantech company in CFIUS analysis related to its business expansion in the U.S.
• Represented a leading 3D printer company in CFIUS analysis related to its business reorganization.
• Represented a leading recruitment and job hunting company in CFIUS and export control analysis related to its business structuring and expansion in the U.S.
• Represented a series of venture capital funds and their portfolio companies in their transaction-based CFIUS analysis and post-closing CFIUS compliance efforts.
• Represented one of the largest credit card payment network companies in the world in its CFIUS analysis, compliance and training programs.
• Represented a leading Chinese textile manufacturer and exporter in response to U.S. sanctions and CBP actions relating to the alleged use of forced labor in the Xinjiang Uyghur Autonomous Region of China.
• Represented a Chinese financial institution in connection with certain semiconductor product and equipment restrictions and foreign direct product rules under the October 7, 2022 export control rules.

Solving Problems – Risk Management, Product Liability Defense, CBP and CPSC Compliance

• Represented a Chinese home appliance manufacturer in handling its product recall in the U.S. and Canada, including negotiating with its U.S. distributor regarding allocation of recall liabilities, preparing responses to CPSC, implementing recall plan and coordinating with insurance carriers.
• Represented a furniture distributor in handling its product recall in the U.S.
• Represented a baby product manufacturer in addressing a CPSC inquiry, successfully mitigating the risk of a product recall.
• Represented a furniture importer in response to CBP and CPSC actions.
• Represented a Chinese consumer product manufacturer in handling a potential product recall in the U.S.
• Represented multiple Chinese manufacturers in handling their product liabilities matters in the U.S., including engaging and coordinating adjusters, negotiating settlement agreements with claimants.
• Represented minority shareholders in protecting their rights and economic stakes in several controlling shareholder dominated situations.
• Represented multiple Chinese companies in handing their disputes with U.S. distributors and customers.